Ranbaxy Granted 60 Days To Produce Audit Documents in DOJ Investigation
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Maryland District Court Judge Peter Messitte has granted a sixty day "abeyance" from a motion filed by the U.S. Department of Justice against Ranbaxy on charges of concealing information regarding one of its manufacturing plants in India
You may also be interested in...
Ranbaxy Internal Audit Disclosure Highlights U.S. FDA Policy Exceptions
Ranbaxy's uphill battle to keep U.S. FDA from seeing a consultant's audit reports provides a sobering reminder of the circumstances under which the agency will seek to review such documents - and the pressure it can exert on a company to release them
Ranbaxy Internal Audit Disclosure Highlights U.S. FDA Policy Exceptions
Ranbaxy's uphill battle to keep U.S. FDA from seeing a consultant's audit reports provides a sobering reminder of the circumstances under which the agency will seek to review such documents - and the pressure it can exert on a company to release them
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
During the last few months, India's largest drug maker Ranbaxy has been in the news more than almost any other manufacturer. Ranbaxy settled patent disputes on two of the largest global drug brands, Lipitor and Nexium. The company's CEO Malvinder Singh sealed a "game-changer" deal with Japan's third largest drug maker Daiichi Sankyo and sold 34.8 percent of his personal and family stake for over $4 billion (PharmAsia News, June 11, 2008). And a U.S FDA investigation of Ranbaxy continues to heat up over allegations of good manufacturing practices deviations at one of the company's manufacturing sites in India (PharmAsia News, July 29, 2008). This week, PharmAsia News' India bureau sat down with Singh to get his take on the action.